A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.

BACKGROUND: We attempted to determine the maximum tolerated dose and toxicity of etoposide (VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route. METHODS AND MATERIALS: A total of 26 patients were treated on this trial. CBD...

Descripción completa

Detalles Bibliográficos
Autores principales: McClay, E. F., Goel, R., Andrews, P., Gorelick, S., Kirmani, S., Kim, S., Braly, P., Plaxe, S., Hoff, S., Alcaraz, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968622/
https://www.ncbi.nlm.nih.gov/pubmed/8398708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968622/
https://www.ncbi.nlm.nih.gov/pubmed/8398708

Ejemplares similares